Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL-7040 · 1 trial · 1 indication
Mayo score assesses stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment. It is assessed according to the following parameters: Stool frequency (subscore 0-3) 0: Normal number of stools for patient 1. 1 to 2 stools per day more than normal 2. 3 to 4 stools more than normal 3. \> or = to 5 stools more than normal Rectal bleeding (subscore 0-3) 0: No blood seen 1. Streaks of blood with stool less than half the time 2. Obvious blood with stool most of the time 3. Blood alone passes Endoscopic findings (subscore 0-3) 0: Normal or inactive disease 1 Mild Disease (erythema, decreased vascular pattern, mild friability) 2: Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3: Severe Disease (spontaneous bleeding, ulceration) Physician's Global Assessment (subscore 0-3) 0: Normal 1. Mild disease 2. Moderate disease 3. Severe disease
| Arm | Type | Description |
|---|---|---|
| A synthetic oligonucleotide for treatment of IBD. | EXPERIMENTAL | BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems. |
| Name | Type | Description |
|---|---|---|
| BL-7040 | DRUG | BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems. Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up. BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days. |
Inclusion Criteria: 1. Male or female, age 18 to 70. 2. Moderately active ulcerative colitis as defined by Mayo score of ≥ 5 and ≤ 9 within 9 days of first day of study treatment. 3. Diagnosis of ulcerative colitis ≥ 3 months prior to study entry. 4. Endoscopic sub-score of ≥ 2 and rectal bleeding ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
BL-7040 is an investigational small molecule being developed for the treatment of ulcerative colitis. It is intended for patients with moderately active ulcerative colitis. The drug is administered orally. As of the available data, BL-7040 is in Phase 2 clinical development and has not been approved by regulatory authorities.
BL-7040 is being developed by BioLineRx Ltd., a biopharmaceutical company. BioLineRx is publicly traded on the NASDAQ under the ticker symbol BLRX. The company is conducting clinical research on BL-7040 for the treatment of ulcerative colitis.
BL-7040 is in Phase 2 clinical development. A Phase 2 clinical trial for BL-7040 has been completed. The drug is investigational and has not been approved for any use. It is being studied for the treatment of moderately active ulcerative colitis.
BL-7040 has one completed clinical trial registered under NCT01506362. The trial was a Phase 2 study titled "Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis." The study enrolled 22 participants in Israel and included adults aged 18 years and older.
BL-7040 is not FDA approved. It is an investigational drug currently in clinical development. A Phase 2 clinical trial for BL-7040 has been completed, but the drug has not received regulatory approval. It is being studied for the treatment of ulcerative colitis.